Methyltransferase Inhibition Enables Tgfβ Driven Induction of CDKN2A and B in Cancer Cells

REFERENCES

• Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol. 2001;2:731–737. doi:10.1038/35096061.
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Flanders TY, Pollock PM, Hayward NK. The CDKN2A (p16) gene and human cancer. Mol Med. 1997;3:5–20. doi:10.1007/BF03401664.
   PubMed Web of Science ®Google Scholar
• Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell. 2006;127:265–275. doi:10.1016/j.cell.2006.10.003.
   PubMed Web of Science ®Google Scholar
• Chen H, Gu X, Su I-h, Bottino R, Contreras JL, Tarakhovsky A, Kim SK. Polycomb protein Ezh2 regulates pancreatic β-cell Ink4a/Arf expression and regeneration in diabetes mellitus. Genes Dev. 2009;23:975–985. doi:10.1101/gad.1742509.
   PubMed Web of Science ®Google Scholar
• Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002;21:5427–5440. doi:10.1038/sj.onc.1205600.
   PubMed Web of Science ®Google Scholar
• Kusy S, Larsen C-J, Roche J. p14ARF, p15INK4b and p16INK4a methylation status in chronic myelogenous leukemia. Leuk Lymphoma. 2004;45:1989–1994. doi:10.1080/10428190410001714025.
   PubMed Web of Science ®Google Scholar
• Martin AC, Thornton JD, Liu J, Wang X, Zuo J, Jablonski MM, Chaum E, Zindy F, Skapek SX. Pathogenesis of persistent hyperplastic primary vitreous in mice lacking the Arf tumor suppressor gene. Invest Ophthalmol Vis Sci. 2004;45:3387–3396. doi:10.1167/iovs.04-0349.
   PubMed Web of Science ®Google Scholar
• McKeller RN, Fowler JL, Cunningham JJ, Warner N, Smeyne RJ, Zindy F, Skapek SX. The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. Proc Natl Acad Sci U S A. 2002;99:3848–3853. doi:10.1073/pnas.052484199.
   PubMed Web of Science ®Google Scholar
• Silva RLA, Thornton JD, Martin AC, Rehg JE, Bertwistle D, Zindy F, Skapek SX. Arf-dependent regulation of Pdgf signaling in perivascular cells in the developing mouse eye. Embo J. 2005;24:2803–2814. doi:10.1038/sj.emboj.7600751.
   PubMedGoogle Scholar
• Freeman-Anderson NE, Zheng Y, McCalla-Martin AC, Treanor LM, Zhao YD, Garfin PM, He T-C, Mary MN, Thornton JD, Anderson C, et al. Expression of the Arf tumor suppressor gene is controlled by Tgfβ2 during development. Development. 2009;136:2081–2089. doi:10.1242/dev.033548.
   PubMedGoogle Scholar
• Zheng Y, Zhao YD, Gibbons M, Abramova T, Chu PY, Ash JD, Cunningham JM, Skapek SX. Tgfβ signaling directly induces Arf promoter remodeling by a mechanism involving Smads 2/3 and p38 MAPK. J Biol Chem. 2010;285:35654–35664. doi:10.1074/jbc.M110.128959.
   PubMedGoogle Scholar
• Zheng Y, Devitt C, Liu J, Iqbal N, Skapek SX. Arf induction by Tgfβ is influenced by Sp1 and C/ebpβ in opposing directions. PLoS One. 2013;8:e70371. doi:10.1371/journal.pone.0070371.
   PubMedGoogle Scholar
• Liu Y-T, Xu L, Bennett L, Hooks JC, Liu J, Zhou Q, Liem P, Zheng Y, Skapek SX. Identification of de novo enhancers activated by TGFβ to drive expression of CDKN2A and B in HeLa cells. Mol Cancer Res. 2019;17:1854–1866. doi:10.1158/1541-7786.MCR-19-0289.
   PubMedGoogle Scholar
• Werness B, Levine A, Howley P. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990;248:76–79. doi:10.1126/science.2157286.
   PubMed Web of Science ®Google Scholar
• Skapek SX, Ferrari A, Gupta AA, Lupo PJ, Butler E, Shipley J, Barr FG, Hawkins DS. Rhabdomyosarcoma. Nat Rev Dis Primers. 2019;5:1. doi:10.1038/s41572-018-0051-2.
   PubMed Web of Science ®Google Scholar
• Saab R, Spunt SL, Skapek SX. Chapter 7 – Myogenesis and rhabdomyosarcoma: the Jekyll and Hyde of skeletal muscle. In: Dyer MA, editors. Current topics in developmental biology. Vol. 94. San Diego (CA): Academic Press; 2011. p. 197–234.
   Google Scholar
• Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014;4:216–231. doi:10.1158/2159-8290.CD-13-0639.
   PubMed Web of Science ®Google Scholar
• Linardic CM, Downie DL, Qualman S, Bentley RC, Counter CM. Genetic modeling of human rhabdomyosarcoma. Cancer Res. 2005;65:4490–4495. doi:10.1158/0008-5472.CAN-04-3194.
   PubMed Web of Science ®Google Scholar
• Linardic CM, Naini S, Herndon JE, II, Kesserwan C, Qualman SJ, Counter CM. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Res. 2007;67:6691–6699.
   PubMed Web of Science ®Google Scholar
• Ren Y-X, Finckenstein FG, Abdueva DA, Shahbazian V, Chung B, Weinberg KI, Triche TJ, Shimada H, Anderson MJ. Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res. 2008;68:6587–6597. doi:10.1158/0008-5472.CAN-08-0859.
   PubMed Web of Science ®Google Scholar
• Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, Wu G, Bradley C, McEvoy J, Pappo A, et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell. 2013;24:710–724. doi:10.1016/j.ccr.2013.11.002.
   PubMed Web of Science ®Google Scholar
• Gil J, Peters G. Regulation of the INK4b–ARF–INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol. 2006;7:667–677. doi:10.1038/nrm1987.
   PubMed Web of Science ®Google Scholar
• Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature. 1994;371:257–261. doi:10.1038/371257a0.
   PubMed Web of Science ®Google Scholar
• Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704–707. doi:10.1038/366704a0.
   PubMed Web of Science ®Google Scholar
• Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 1995;83:993–1000.
   PubMed Web of Science ®Google Scholar
• Michael D, Oren M. The p53–Mdm2 module and the ubiquitin system. Semin Cancer Biol. 2003;13:49–58. doi:10.1016/S1044-579X(02)00099-8.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA. Neuroblastoma. Nat Rev Dis Primers. 2016;2:16078. doi:10.1038/nrdp.2016.78.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Devitt C, Liu J, Mei J, Skapek SX. A distant, cis-acting enhancer drives induction of Arf by Tgfβ in the developing eye. Dev Biol. 2013;380:49–57. doi:10.1016/j.ydbio.2013.05.003.
   PubMedGoogle Scholar
• Calo E, Wysocka J. Modification of enhancer chromatin: what, how, and why? Mol Cell. 2013;49:825–837. doi:10.1016/j.molcel.2013.01.038.
   PubMed Web of Science ®Google Scholar
• Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002;298:1039–1043. doi:10.1126/science.1076997.
   PubMed Web of Science ®Google Scholar
• Xu L, Zheng Y, Liu J, Rakheja D, Singleterry S, Laetsch TW, Shern JF, Khan J, Triche TJ, Hawkins DS, et al. Integrative Bayesian analysis identifies rhabdomyosarcoma disease genes. Cell Rep. 2018;24:238–251. doi:10.1016/j.celrep.2018.06.006.
   PubMedGoogle Scholar
• Ciarapica R, Russo G, Verginelli F, Raimondi L, Donfrancesco A, Rota R, Giordano A. Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle. 2009;8:172–175. doi:10.4161/cc.8.1.7292.
   PubMed Web of Science ®Google Scholar
• Marchesi I, Fiorentino FP, Rizzolio F, Giordano A, Bagella L. The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation. Cell Cycle. 2012;11:3828–3836. doi:10.4161/cc.22025.
   PubMed Web of Science ®Google Scholar
• Glazer RI, Knode MC, Tseng CKH, Haines DR, Marquez VE. 3-deazaneplanocin A: a new inhibitor of S-adenosylhomocysteine synthesis and its effects in human colon carcinoma cells. Biochem Pharmacol. 1986;35:4523–4527. doi:10.1016/0006-2952(86)90774-4.
   PubMed Web of Science ®Google Scholar
• Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RKM, Tan PBO, Liu ET, Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007;21:1050–1063. doi:10.1101/gad.1524107.
   PubMed Web of Science ®Google Scholar
• Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, Marquez VE, Jones PA. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther. 2009;8:1579–1588. doi:10.1158/1535-7163.MCT-09-0013.
   PubMed Web of Science ®Google Scholar
• Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, Scott MP, Chesworth R, Moyer MP, Copeland RA, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A. 2013;110:7922–7927. doi:10.1073/pnas.1303800110.
   PubMed Web of Science ®Google Scholar
• Farooq U, Saravanan B, Islam Z, Walavalkar K, Singh AK, Jayani RS, Meel S, Swaminathan S, Notani D. An interdependent network of functional enhancers regulates transcription and EZH2 loading at the INK4a/ARF locus. Cell Rep. 2021;34:108898. doi:10.1016/j.celrep.2021.108898.
   PubMedGoogle Scholar
• Cheng AW, Wang H, Yang H, Shi L, Katz Y, Theunissen TW, Rangarajan S, Shivalila CS, Dadon DB, Jaenisch R. Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res. 2013;23:1163–1171. doi:10.1038/cr.2013.122.
   PubMed Web of Science ®Google Scholar
• Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, Guimaraes C, Panning B, Ploegh HL, Bassik MC, et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell. 2014;159:647–661. doi:10.1016/j.cell.2014.09.029.
   PubMed Web of Science ®Google Scholar
• Chavez A, Scheiman J, Vora S, Pruitt BW, Tuttle M, P R Iyer E, Lin S, Kiani S, Guzman CD, Wiegand DJ, et al. Highly efficient Cas9-mediated transcriptional programming. Nat Methods. 2015;12:326–328. doi:10.1038/nmeth.3312.
   PubMed Web of Science ®Google Scholar
• Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N, Brandman O, Whitehead EH, Doudna JA, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013;154:442–451. doi:10.1016/j.cell.2013.06.044.
   PubMed Web of Science ®Google Scholar
• Hannigan A, Smith P, Kalna G, Lo Nigro C, Orang’ C, O'Brien DI, Shah R, Syed N, Spender LC, Herrera B, et al. Epigenetic downregulation of human disabled homolog 2 switches TGF-β from a tumor suppressor to a tumor promoter. J Clin Invest. 2010;120:2842–2857. doi:10.1172/JCI36125.
   PubMedGoogle Scholar
• Lee S-H, Kim O, Kim H-J, Hwangbo C, Lee J-H. Epigenetic regulation of TGF-β-induced EMT by JMJD3/KDM6B histone H3K27 demethylase. Oncogenesis. 2021;10:17. doi:10.1038/s41389-021-00307-0.
   PubMedGoogle Scholar
• Vinchure OS, Sharma V, Tabasum S, Ghosh S, Singh RP, Sarkar C, Kulshreshtha R. Polycomb complex mediated epigenetic reprogramming alters TGF-β signaling via a novel EZH2/miR-490/TGIF2 axis thereby inducing migration and EMT potential in glioblastomas. Int J Cancer. 2019;145:1254–1269. doi:10.1002/ijc.32360.
   PubMedGoogle Scholar
• Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, Jonasdottir A, Sigurdsson A, Baker A, Palsson A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316:1491–1493. doi:10.1126/science.1142842.
   PubMed Web of Science ®Google Scholar
• McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316:1488–1491. doi:10.1126/science.1142447.
   PubMed Web of Science ®Google Scholar
• Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund P, Wichmann H-E, et al. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007;357:443–453. doi:10.1056/NEJMoa072366.
   PubMed Web of Science ®Google Scholar
• Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007;316:1331–1336. doi:10.1126/science.1142358.
   PubMed Web of Science ®Google Scholar
• Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science. 2007;316:1341–1345. doi:10.1126/science.1142382.
   PubMed Web of Science ®Google Scholar
• Emanuele E, Lista S, Ghidoni R, Binetti G, Cereda C, Benussi L, Maletta R, Bruni AC, Politi P. Chromosome 9p21.3 genotype is associated with vascular dementia and Alzheimer’s disease. Neurobiol Aging. 2011;32:1231–1235. doi:10.1016/j.neurobiolaging.2009.07.003.
   PubMedGoogle Scholar
• Züchner S, Gilbert JR, Martin ER, Leon-Guerrero CR, Xu P-T, Browning C, Bronson PG, Whitehead P, Schmechel DE, Haines JL, et al. Linkage and association study of late-onset Alzheimer disease families linked to 9p21.3. Ann Hum Genet. 2008;72:725–731. doi:10.1111/j.1469-1809.2008.00474.x.
   PubMed Web of Science ®Google Scholar
• Visel A, Zhu Y, May D, Afzal V, Gong E, Attanasio C, Blow MJ, Cohen JC, Rubin EM, Pennacchio LA. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature. 2010;464:409–412. doi:10.1038/nature08801.
   PubMed Web of Science ®Google Scholar
• Widau RC, Zheng Y, Sung CY, Zelivianskaia A, Roach LE, Bachmeyer KM, Abramova T, Desgardin A, Rosner A, Cunningham JM, et al. p19Arf represses platelet-derived growth factor receptor β by transcriptional and posttranscriptional mechanisms. Mol Cell Biol. 2012;32:4270–4282. doi:10.1128/MCB.06424-11.
   PubMedGoogle Scholar
• Pasmant E, Laurendeau I, Héron D, Vidaud M, Vidaud D, Bièche I. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res. 2007;67:3963–3969. doi:10.1158/0008-5472.CAN-06-2004.
   PubMed Web of Science ®Google Scholar
• Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, Xiong Y. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15INK4B tumor suppressor gene. Oncogene. 2011;30:1956–1962. doi:10.1038/onc.2010.568.
   PubMed Web of Science ®Google Scholar
• Ciarapica R, Carcarino E, Adesso L, De Salvo M, Bracaglia G, Leoncini PP, Dall’Agnese A, Verginelli F, Milano GM, Boldrini R, et al. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS. BMC Cancer. 2014;14:139. doi:10.1186/1471-2407-14-139.
   PubMedGoogle Scholar
• Tarnowski M, Tkacz M, Czerewaty M, Poniewierska‑Baran A, Grymuła K, Ratajczak MZ. 5‑Azacytidine inhibits human rhabdomyosarcoma cell growth by downregulating insulin‑like growth factor 2 expression and reactivating the H19 gene product miR‑675, which negatively affects insulin‑like growth factors and insulin signaling. Int J Oncol. 2015;46:2241–2250. doi:10.3892/ijo.2015.2906.
   PubMedGoogle Scholar
• Labun K, Montague TG, Gagnon JA, Thyme SB, Valen E. CHOPCHOP v2: a web tool for the next generation of CRISPR genome engineering. Nucleic Acids Res. 2016;44:W272–W276. doi:10.1093/nar/gkw398.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Xu L, Hassan M, Zhou X, Zhou Q, Rakheja D, Skapek SX. Bayesian modeling identifies PLAG1 as a key regulator of proliferation and survival in rhabdomyosarcoma cells. Mol Cancer Res. 2020;18:364–374. doi:10.1158/1541-7786.MCR-19-0764.
   PubMedGoogle Scholar